Repurposing of thalidomide and its derivatives for the treatment of SARS-coV-2 infections: Hints on molecular action

Lakshmikirupa Sundaresan\(^3\) \| Suvendu Giri\(^1,2\) \| Himanshi Singh\(^1,2\) \| Suvro Chatterjee\(^1,2\)

1Vascular Biology Laboratory, AU-KBC Research Centre, Chennai, India
2Department of Biotechnology, Anna University, Chennai, India
3Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada

**Correspondence**
Suvro Chatterjee, Ph.D, AU-KBC Research Centre, MIT Campus of Anna University, Chromepet Chennai-600044, India.
Email: soovro@yahoo.ca

**Funding information**
University Grant Commission-Faculty Recharge Programme (UGC-FRP), Government of India to S.C

**Aims:** The SARS-coV-2 pandemic continues to cause an unprecedented global destabilization requiring urgent attention towards drug and vaccine development. Thalidomide, a drug with known anti-inflammatory and immunomodulatory effects has been indicated to be effective in treating a SARS-coV-2 pneumonia patient. Here, we study the possible mechanisms through which thalidomide might affect coronavirus disease-19 (COVID-19).

**Methods:** The present study explores the possibility of repurposing thalidomide for the treatment of SARS-coV-2 pneumonia by reanalysing transcriptomes of SARS-coV-2 infected tissues with thalidomide and lenalidomide induced transcriptomic changes in transformed lung and haematopoietic models as procured from databases, and further comparing them with the transcriptome of primary endothelial cells.

**Results:** Thalidomide and lenalidomide exhibited pleiotropic effects affecting a range of biological processes including inflammation, immune response, angiogenesis, MAPK signalling, NOD-like receptor signalling, Toll-like receptor signalling, leucocyte differentiation and innate immunity, the processes that are aberrantly regulated in severe COVID-19 patients.

**Conclusion:** The present study indicates thalidomide analogues as a better fit for treating severe cases of novel viral infections, healing the damaged network by compensating the impairment caused by the COVID-19.

**KEYWORDS**
angiogenesis, COVID-19, endothelium, immune response, inflammation, lenalidomide, SARS-coV-2, thalidomide

**1 | INTRODUCTION**

Novel coronavirus, SARS-coV-2 has been posing devastating effects on a global scale with a soaring number of infections and an alarming rate of mortality. Along with the tremendous efforts to develop vaccines, repurposing of drugs with known safety and efficacy profiles is one of the viable choices for treatment. Coronavirus disease-19 (COVID-19) is clinically very challenging since the novel coronavirus triggers multiorgan turbulence devastating the homeostasis of the human system. Once the SARS-CoV-2 virus enters the respiratory tract, there are 4 different stages of the infection from symptoms to multiorgan failures. Phase I begins with the naso-oral viral entry followed by host immune system alert with active viral replication in the upper respiratory tract (Phase II). In Phase III, a minor cytokine storm occurs in the alveoli, releasing the inflammatory cytokines resulting in leaky blood vessels, which is followed by the second
cytokine storm with uncontrolled inflammatory and life-threatening symptoms, acute respiratory distress syndrome (ARDS), seizure, severe hypoxia and severed organ toxicity (Phase IV).\(^1\)\(^,\)\(^2\) Manifestation of the biphasic cytokine storm occurs through the activation of a series of cytokines including monocyte chemotactant protein 1 (CCL2), macrophage inflammatory protein 1α (MIP-1α), tumour necrosis factor α (TNF-α), interleukin (IL)-2R and IL-6 overwhelming the system leading to indiscriminate damages in multiple organs.\(^3\)\(^-\)\(^5\) There is an increased amount of blood vessel growth in the lungs of COVID-19 patients compared to severe influenza.\(^6\) As COVID-19 is a multilayer problem, researchers around the world are desperately in search for a drug, which would able to tackle all or few of these COVID-19 hallmarks.

**Thalidomide**, a small molecule drug, with many years of history known to cause misery,\(^7\) became a game changer for its multifaceted pharmacological effects such as immunomodulation, anti-inflammation, antiangiogenesis and antiviral effects.\(^8\) At present, the world needs a smart solution. Thalidomide increases the hope of treating COVID-19 patients.\(^9\) Chen et al. report successful treatment of SARS-coV-2 associated pneumonia with combinatory treatment of thalidomide and a low-dose glucocorticoid.\(^10\) Two clinical trials, NCT04273581 and NCT04273529 have been registered to check the efficacy of thalidomide in treating COVID-19 patients. The adverse effects of thalidomide and its analogues are well documented.\(^11\)

Extensive information available on thalidomide’s mechanisms, its efficacy and safety in haemophagocytic syndrome-induced cytokine storm\(^12\) and idiopathic pulmonary fibrosis,\(^13\) severe H1N1, and paraquat poisoning lung injury\(^14\)\(^,\)\(^15\) argues for the possible action of thalidomide on COVID-19 induced lung effects and cytokine storm. Recent reviews on thalidomide in COVID-19 treatment endorse the possibility of thalidomide and its analogues for the treatment of COVID-19 symptoms.\(^16\)\(^,\)\(^17\)

Transcriptome-based approach to connect diseases with drug responses is a recognized strategy in drug repurposing.\(^18\) With the fast-growing literature on SARS-coV-2 infections, we performed a combined analysis of whole transcriptome signatures of lungs, peripheral blood mononuclear cells (PBMC), bronchoalveolar lavage fluid (BALF) from SARS-coV-2 affected patients and A549 cells (transformed adenocarcinoma cells), and compared with the gene expression signatures of A549 cells treated with thalidomide or lenalidomide, haematopoietic cells, and human umbilical vein endothelial cells (HUVEC). We hereby provide possible mechanistic actions of thalidomide in treating the SARS-coV-2 pathology. In addition, we suggest that the derivatives of thalidomide, lenalidomide and **CC-220** might also be effective in the treatment of SARS-coV-2.

### 2 | METHODS

#### 2.1 | Data collection

A total of 16 gene expression datasets including 15 publicly available expression datasets were included in this study. Transcriptomes of SARS-coV-2 infected lung tissues matched with healthy control and SARS-coV-2 treated A549 cells were obtained from GEO (Accession ID: GSE147507).\(^19\) Transcriptome data of BALF and PBMC were obtained from BIG Data Center (https://bigd.big.ac.cn/; Accession ID: CRA002390).\(^20\) The expression profiles of systemic lupus erythematosus (Accession ID: GSE112087),\(^21\) bone marrow cells treated with lenalidomide (Accession ID: GSE106748),\(^22\) lymphoma cells treated with lenalidomide (Accession ID: GSE60618),\(^23\) CD34-positive cells treated with **pomalidomide** (Accession ID: GSE144052), MERS infected PBMC (Accession: GSE1739),\(^24\) lenalidomide-treated PBMC (Accession ID: GSE84251) and CC-122 treated lymphoma cells (Accession ID: GSE75420)\(^25\) were procured from GEO and differentially expressed genes (DEGs) were identified using limma.\(^26\) Library of Integrated Network-Based Cellular Signatures (iLINCS) is a database that contains the gene expression signatures of >21,000 compounds (http://www.ilincs.org/ilincs/). We obtained the gene expression signatures for A549 cells treated with 10 μM thalidomide for 6 hours (LINSCP_4683) and 24 hours (LINSCP_4463), 100 μM lenalidomide for 6 hours (LINSCP_4650) and 24 h (LINSCP_4427).

#### 2.2 | Transcriptome sequencing of HUVEC treated with thalidomide

Endothelitis is a common sign of COVID-19\(^6\) and as thalidomide possesses well established vascular and anti-inflammatory effects, we...
attempted to explore the effects of thalidomide and its derivatives on endothelium. HUVEC were subjected to 20 μM thalidomide or 20 μM lenalidomide or 20 μM pomalidomide or vehicle control treatment for 8 hours. RNA was isolated using TRizol method and whole transcriptome sequencing was performed using Illumina HiSeq 2500 platform. The data can be accessed at GEO with the Accession ID GSE118979. The sequence reads were aligned with reference genome of Homo sapiens using TopHat2 (v2.0.8) and then followed by transcript compilation and gene identification was done using Cufflinks (v2.2.0). The DEGs were identified using Cuffdiff program (v2.2.0).

2.3 | Differential expression and enrichment analysis

The raw counts from the SARS-cov-2 transcriptomic profiles were subjected to differential expression analysis by DESeq2 v1.26.0. Subsequently the genes were pre-ranked using the P-values from DESeq2 analysis and subjected to pre-ranked gene set enrichment analysis. Gene sets with false discovery rate < 0.05 were considered to be statistically significant and were visualized using EnrichmentMap plugin of Cytoscape. For drug signatures from iLINCS, differentially expressed genes with P < 0.05 were considered to be statistically significant. Enrichment of kinase perturbation was carried out using Enrichr.

2.4 | KINOMEscan kinase screening

We analysed our previously published KINOMEscan kinase screening dataset of thalidomide in order to investigate how thalidomide affects the immune system. Kinases whose activities were reduced at least by 60% were considered for further enrichment analysis.

2.5 | Comparative analysis using Topocluster

The DEGs (Q < 0.05 for transcriptome and P < 0.05 for drug signatures) from all the gene expression profiles were compared for overlapping genes and over-represented pathways using Topocluster and the networks were visualized using in Cytoscape.

2.6 | Identification of protein targets using PharmMapper

For identifying the protein targets of thalidomide, we utilized the PharmMapper server (http://www.lilab-ecust.cn/pharmmapper/). The server identifies possible physiological protein targets of any drug molecule by using a pharmacophore-based mapping approach. The 3-dimensional structure of thalidomide was obtained from PubChem and processed on the PharmMapper server choosing only human protein target sets. The top 100 target proteins were selected based on the ranking associated with a fit score (pKd value) for further enrichment analysis using Enrichr.

3 | RESULTS

3.1 | Meta-analysis of SARS-cov-2 affected lung biopsies and PBMCs reveal enrichment of various pathways pertaining to immune response

We reanalysed and compared the SARS-cov-2 infected lung biopsies, A549 cells, PBMC and BALF transcriptomic profiles obtained from different studies. SARS-cov-2 infection showed a massive surge in inflammatory response, cytokine production and cytokine-mediated signalling. There was a substantial upregulation of immune response including the processes of haematopoietic development and lymphocyte activation (Figures 1A, 5A, S3A). Activation of viral life cycle and antiviral interferon signalling was observed in infected lungs (Figure 1A) and A549 cells (Figures 1B, S7). Over-representation of pathways including NOD-like receptor signalling, MAPK cascade, measles and influenza-A were seen in the infected lung as identified by gene set enrichment analysis (Figure 1A). Enrichr analysis revealed that many genes upregulated in SARS-cov-2 lung are the genes downregulated when SYK was knocked down or inhibited as supported by previous GEO studies (GSE43510, GDS3609 and GSE34176; Figure 1C). Expression to kinase (X2K) analysis showed the possible perturbation of various MAP kinases including ABL1 and JNK1 (Figures S1A, S1B). Human phenotype enrichment analysis shows thrombocytopenia, poor wound healing, abnormality of lymphatic system, serositis and abnormal anticoagulant pathways in SARS-cov-2 infected lungs (Figure S5).

3.2 | Similarity of SARS-cov-2 expression profile with that of systemic lupus erythematosus, lymphoma and multiple myeloma

Comparative enrichment analysis of gene expression profiles for disease-specific phenotypes revealed the similarity of SARS-infected tissues with pneumonia, influenza, lymphoma, systemic lupus erythematosus (SLE), multiple myeloma, asthma, auto-immune diseases, asthma, pneumonia and atherosclerosis while SARS-cov-2 PBMC showed exclusive overlap with lymphoma, multiple myeloma and chronic lymphocytic leukemia (Figure 2A). The gene expression profile of SARS-cov-2 infected lungs showed high resemblance to that of PBMC from SLE patients (Figure 2B). There was a significant overlap between SARS-cov-2 and SLE in upregulated genes involved in immune regulation (Figure S3A), interferon signalling (Figure S7B) and disease-specific phenotypes including lymphoma and multiple myeloma (Figures S2A, S2B, S2C). Targets of transcription factors, IFN-sensitive response element and IFN-regulatory factor (IRF) were upregulated in SARS-cov-2 affected lungs similar to upregulation observed in the PBMC of SLE patients (Figures 1B, S1C).
3.3 Effect of thalidomide on kinases implicated in immune response and MAPK signalling

The kinase screening assay on thalidomide identified key kinases involved in the regulation of immune response. The most kinases affected were LCK and SYK (Figure 3C), critical modulators of T cell receptor signalling. Many LCK substrates, SPI1, TBK1, FOXP3, EGR1, ESR1, IRF1, CBL and STAT1 as well as SYK phosphorylation targets such as OAS1 and MX1 were upregulated in SARS-coV-2 lung (Figure s4, S1). Various processes mediating immune response...
including JUN phosphorylation, IκB phosphorylation, JAK-STAT pathway, leucocyte-mediated immunity, neutrophil degranulation and activation, B-cell receptor signalling, and MAPK cascade were found to be affected by thalidomide (Figure 3D). We studied the effects of thalidomide and its derivatives on endothelium and identified the downregulation of several angiogenic genes (Figure 4B and Table 1).
PharmMapper results showed strong affinity for LCK, HCK and SYK along with other proteins involved in innate and adaptive immune response (Table 2).

3.4 | Upregulated pathways and gene ontology biological processes in SARS-coV-2 infection suppressed by thalidomide and lenalidomide

Various genes aberrantly expressed in SARS-coV-2 affected lungs are known targets of thalidomide (Table 1). SARS-coV-2 infected lungs, PBMC and A549 cells showed significant upregulation of expression of genes involved in inflammation, cytokine signalling, MAPK signalling and activation of cells mediating the immune response whereas BALF exhibited a slightly different immune profile where leucocyte and neutrophil activation was suppressed (Figure 5A). Comparison of differentially expressed genes of all the signatures yielded interesting results. Many of the processes upregulated in SARS-coV-2 infected tissues were suppressed by thalidomide and lenalidomide in A549 cells and endothelial cells (Figures 3A,B, 5A). Thalidomide-treated A549 cells showed suppression of key genes including SYK, JUN, PIK3CA and HLA genes implicated in immune response (Figure S3A,B). Thalidomide and lenalidomide down-regulated various proinflammatory and angiogenic genes aberrantly expressed in SARS-cov-2 infected lungs including CCL2 and TSC22D3 which are NF-κB modulators in A549 cells (Figure 4A,B). Thalidomide

**FIGURE 3** Effect of thalidomide and lenalidomide on immune system. Gene set enrichment analysis network of gene expression profiles of (A) thalidomide and (B) lenalidomide-treated A549 cells. (C) Activities of kinase involved in immunomodulation and MAPK signalling in the presence of thalidomide. (D) Biological pathways enriched by kinases affected by thalidomide.
and lenalidomide treatment resulted in significant suppression of cytokine response, angiogenesis, inflammation, Fc Epsilon receptor signalling and MAPK cascade (Figure 3A). In addition, lenalidomide downregulated STAT1 expression, leucocyte differentiation, TLR signalling as well as IRF activation (Figures 3B, S4B). Many genes implicated in NOD-like receptor signalling overexpressed in SARS-coV-2 were suppressed by lenalidomide in A549 and lymphoma cells (Figure S4C). B-cell receptor signalling was activated in SARS-CoV-2 affected PBMC whereas T-cell activation was observed in SARS-CoV-2 lungs (Figure S3B). Translation of viral mRNA was exclusively observed in SARS-CoV-2 infected BALF whereas genes implicated in viral entry and life cycle were upregulated in SARS-CoV-2 infected lungs, BALF and A549 cells. Genes involved in viral entry and type I interferon signalling were downregulated in thalidomide-treated A549 cells and lenalidomide-treated lymphoma, A549 and HUVEC (Figures S7A, S7C). Several aberrantly expressed genes involved in these disease phenotypes were downregulated in thalidomide and lenalidomide treated A549 and endothelium (Figure 2).

### DISCUSSION

SARS-CoV-2 infection causes surge in a number of pathways related to inflammation, cytokine signalling, leucocyte and lymphocyte...
activation, innate and adaptive immune response marking the phenomenon of cytokine storm. As the whole immune system is affected during the SARS-CoV-2 infection, immunomodulators would be highly beneficial in treating the symptoms. A COVID-19 patient with pneumonia was treated successfully with thalidomide and low-dose glucocorticoid. There was a significant decrease in the inflammatory cytokines including IL-1, IL-6 and IFN-γ and increase in the CD4 + and CD8 + T cells and NK cells. Thalidomide reduced the severity of many COVID-19 symptoms such as lung lesions, exudation due to its pleiotropic effects on the human system.10 Haemophagocytic syndrome, a hyperinflammatory disorder is another condition in which cytokine storm occurs. It is frequently present with extranodal natural killer/T cell lymphoma (ENKTL). Thalidomide was effective in suppressing the cytokine storm through inhibition of NF-κB based transcription of IFN-γ and TNF genes and thalidomide along with P-Gemox was highly effective in treating ENKTL patients in a Phase II clinical trial.58 Comparison of SARS-CoV-2 expression profiles with drug signatures through enrichment analysis revealed striking actions of thalidomide and lenalidomide in A549 cells and lymphoma. The signatures of MERS-affected and systemic lupus erythematosus patients were used for comparison.
effects of SARS-cov-2 infections on immune system. We selected A549, an adenocarcinomic human alveolar basal epithelial cell line to test our hypothesis that thalidomide would be effective against the cytokine storms. The A549 cell line is an appropriate model for testing thalidomide’s effects on gene expression and cytokine storms. The A549 cell line is an appropriate model for testing our hypothesis that thalidomide would be effective against the cytokine storm targeting drugs since a previous study established this model by infecting the cells with influenza A/H1N1 virus (PR-8) or nonstructural protein 1 plasmid to test the mechanisms behind inflammatory cytokines/chemokines mediated cytokine storm. Studies have utilized A549 cells to show the effects of thalidomide on lung fibrosis. A limitation of this study is that only 978 genes called landmark genes are profiled in the iLINCS drug signatures. However, the profiles are highly reproducible and represent the whole transcriptome. Our models of A549 and HUVEC effectively capture the effects of thalidomide in lungs as well as endothelium.

It is also emerging that SARS-cov-2 infections perturb vascular plexus significantly and there is a substantial increase in the growth of new blood vessels and evidence of intussusceptive angiogenesis with overexpression of angiogenesis and hypoxia genes in the lungs of COVID-19 patients. Cytokine storm and atherosclerosis are tightly connected in SARS-cov-2, which is consistent with our analysis revealing the enrichment of atherosclerosis in the SARS-cov-2 signatures (Figure 2A). Thalidomide is a renowned modulator of vascular system, and it is known to transcriptionally or functionally target various genes (Table 1) upregulated in the lungs of COVID-19 patients. As SARS-cov-2 infection has a huge impact on the haematopoietic system affecting the myeloid cell maturation, we reanalysed the effects of thalidomide and its derivatives on PBMC, bone marrow cells as well as lymphoma cells. Thalidomide and lenalidomide exhibited attenuation of cytokine signalling and inflammation in addition to its anti-angiogenic action (Figure 3A). The drugs affected most of the pathways upregulated in SARS-cov-2 affected lungs and PBMC (Figures 1A, 3A) in A549 cells, mandating direct investigations in SARS-cov-2 infected models.

COVID-19 coincides with a strong neuro-endocrine modulation because the disease devastates functions of the organs, and naturally the reciprocal communication between the organs of the endocrine stress system gets a set-back. ACE2 is expressed along the hypothalamus, pituitary and adrenal axis which is implicated in the stress response and adrenal glands has the highest concentration of virus particles next to lung. A high expression of ACE2 in brain is believed to be the reason for the possible infection of the central nervous system in SARS patients. Chronic elevated stress levels have been reported in SARS and SARS-cov-2 patients even long after the outbreak. Notably, thalidomide is also known for its neuro-endocrine modulation properties. Thalidomide modulates the central nervous system by reducing the generation of proinflammatory cytokines such as IL-1, IL-6, IL-8 and TNF-α through NF-κB inhibition. There was a downregulation of genes involved in circadian wake cycle (Figures 1B, S2) including PER3 in the PBMC of COVID-19 patients, suggesting a reason for the possible sleep disturbances in SARS-cov-2 patients. Thalidomide, having a well-known antiemetic and sedative action on the neuroendocrine axis, would relax the patients, which is supported by the report that thalidomide was effective in treating the anxiety and digestive symptoms in COVID-19 patients.

The anti-inflammatory properties of thalidomide and its analogues through reduction of IL-1β, TNF-α expression and NF-κB inhibition are well established. SARS-cov-2 infections showing

| Gene         | SARS-coV2-lung | Thalidomide or lenalidomide treatment |
|--------------|---------------|-------------------------------------|
| AKT1, AKT2   | Uregulation   | Signalling—Down                   |
| ANGPTL4      | Uregulation   | Down                                |
| CDC42        | Uregulation   | Down                                |
| COL1A1*      | Uregulation   | Down                                |
| COL1A2*      | Uregulation   | Down                                |
| MMP2         | Uregulation   | Down                                |
| THBS2*       | Uregulation   | Down (present study)               |
| VEGFA        | Uregulation   | Down                                |
| VEGFC        | Uregulation   | Down                                |
| FGF2*        | Uregulation   | Down                                |
| FLT1         | Uregulation   | Down                                |
| FN1          | Uregulation   | Down                                |
| HIF1A        | Uregulation   | Down                                |
| IGF1         | Uregulation   | Down                                |
| MMP14        | Uregulation   | Down                                |
| RBPJ         | Uregulation   | Down                                |
| TIMP1        | Uregulation   | Down                                |
| VCAM1        | Uregulation   | Down                                |
| IFN-γ        | Uregulation   | Down                                |
| IL-6         | Uregulation   | Down                                |
| HGF          | Uregulation   | Down                                |
| IL-10        | Uregulation   | Down                                |
| IL-1β        | Uregulation   | Down                                |
| CTNNB1*      | Uregulation   | Down                                |
| MCP1*        | Uregulation   | Down                                |
| NF-κB*       | Uregulation   | Down                                |
| TNF-α        | Uregulation   | Down                                |
| GREM1*       | Uregulation   | Down (present study)               |
| STAT1*       | Uregulation   | Down                                |
| NOS3         | Uregulation   | Down                                |
| CASP8        | Uregulation   | Down                                |
| MAP 2 K1     | Uregulation   | Down                                |
| PTEN         | Uregulation   | Up                                  |
| IL-2         | Uregulation   | Up                                  |
| BMP7         | Uregulation   | Up                                  |
| MIP-α        | Uregulation   | Up/down                             |
| SPARC        | Uregulation   | Up                                  |
| NRPI         | Uregulation   | Up                                  |

*Downregulation of genes/pathways observed in the present study as well.
**Table 2** Biological processes and pathways enriched by Pharmmapper predicted protein targets of thalidomide, lenalidomide and pomalidomide

| Pharmmapper identified protein targets of thalidomide and enriched biological processes and pathways | Overlap* | Adjusted P-value** | Genes |
|---|---|---|---|
| Innate immune system Homo sapiens R-HSA-168249 | 36/807 | 1.19E-10 | ITK; GSK3B; SRC; CTSS; EGFR; MAPK8; CTSL; AKT2; CTSK; ABL1; CASP1; AKT1; MAPK1; JAK3; HRAS; MAP 2 K1; HSP90AA1; SYK; PDPK1; FGG; MAPK14; PTK2; IL2; MAPK10; HCK; LCK; KIT; MAPKAPK2; BTK; BTK; MDM2; PRRKQ; BPI; TEK; RAF1; FGFR2 |
| B-cell receptor signalling pathway WP23 | 13/97 | 7.96E-10 | GSK3B; MAP 2 K1; SYK; PDPK1; MAPK14; MAPK8; LCK; BTK; RAC2; AKT1; MAPK1; RAF1; HRAS |
| MAPK signalling pathway | 24/295 | 7.42E-13 | HSPA8; MAP 2 K1; IGF1; MAPK14; EGFR; TGFBR1; IGF1R; MAPK10; MAPK8; AKT2; CASP3; KIT; AKPAPK2; KDR; RAC2; AKT1; MAPK1; TEK; RAF1; HRAS; MET; HSPA1B; FGFR2; HSPA1A |
| Interleukin signalling pathway Homo sapiens P00036 | 9/86 | 3.40E-06 | GSK3B; PDPK1; AKT2; MAPKAPK2; AKT1; MAPK1; RAF1; JAK3; IL2 |
| Interferon-γ signalling pathway Homo sapiens P00035 | 4/28 | 1.09E-03 | MAPK10; MAPK8; MAPK1; MAPK14 |
| Inflammation mediated by chemokine and cytokine signalling pathway Homo sapiens P00031 | 9/188 | 1.05E-03 | ROCK1; PDPK1; AKT2; ACT1; MAPK1; RAF1; ITGAL; IL2; RHOA |
| IL-3 signalling pathway WP286 | 9/49 | 2.60E-08 | HCK; MAP 2 K1; MAPK8; SYK; SRC; AKT1; MAPK1; RAF1; HRAS |
| T-cell receptor signalling pathway | 15/101 | 6.87E-12 | ITK; GSK3B; MAP 2 K1; PDPK1; MAPK14; IL2; RHOA; ZAP70; LCK; AKT2; AKT1; MAPK1; PRRKQ; RAF1; HRAS |
| Melanoma | 12/72 | 2.16E-10 | MAP 2 K1; CDK6; AKT2; MDM2; AKT1; MAPK1; IGF1; RAF1; HRAS; MET; EGFR; IGF1R |
| Measles | 14/138 | 3.11E-09 | HSPA8; GSK3B; IL2; MAPK10; MAPK8; CDK6; AKT2; MAPKAPK2; CDK2; AKT1; RAB9A; JAK3; HSPA1B; HSPA1A |
| Osteoclast differentiation | 13/127 | 9.88E-09 | MAP 2 K1; SYK; MAPK14; TGFBR1; MAPK10; MAPK8; LCK; AKT2; CTSK; BTK; AKT1; MAPK1; PPARG |
| Chemokine signalling pathway | 15/190 | 1.77E-08 | ITK; GSK3B; MAP 2 K1; ROCK1; SRC; PTK2; RHOA; HCK; AKT2; RAC2; AKT1; MAPK1; RAF1; HRAS; JAK3 |

| Pharmmapper identified protein targets of lenalidomide and enriched biological processes and pathways | Overlap* | Adjusted P-value** | Genes |
|---|---|---|---|
| Innate immune system Homo sapiens R-HSA-168249 | 22/807 | 7.02E-05 | GSK3B; ITK; HSP90AA1; PDPK1; SRC; FGG; MAPK14; PTK2; CTSS; MAPK10; LCK; AKT2; CTSL; MAPKAPK2; KIT; BTK; CTSK; BTK; BTK; ABL1; BPI; TEK; RAF1; HRAS |
| Toll-like receptors cascades Homo sapiens R-HSA-168898 | 8/140 | 7.97E-04 | MAPK10; CTSK; MAPKAPK2; BTK; MAPK1; bpi; MAPK14; CTSS |
| Adaptive immune system Homo sapiens R-HSA-1280218 | 15/762 | 0.16 | GSK3B; ITK; PDPK1; SRC; KIF11; CTSS; ZAP70; LCK; AKT2; CTSK; kit; BTK; MAPK1; RAF1; HRAS |
| B cell activation Homo sapiens P00010 | 7/57 | 7.43E-06 | MAPK10; RAC2; BTK; MAPK1; RAF1; MAPK14; HRAS |
| T cell receptor signalling pathway | 11/101 | 3.16E-08 | ITK; GSK3B; ZAP70; PDPK1; LCK; AKT2; MAPK1; RAF1; MAPK14; HRAS; RHOA |
| Fc epsilon RI signalling pathway | 9/68 | 1.13E-07 | MAPK10; PDPK1; AKT2; RAC2; BTK; MAPK1; RAF1; MAPK14; HRAS |
| IL-17 signalling pathway | 10/93 | 1.15E-07 | MAPK10; GSK3B; HSP90AA1; MMP13; MMP1; CASP3; MMP3; MAPK1; MAPK14; MMP9 |
| MAPK signalling pathway | 15/295 | 4.32E-07 | MAPK14; MAPK10; AKT2; CASP3; MAPKAPK2; KIT; KDR; RAC2; MAPK1; TEK; RAF1; HRAS; MET; HSPA1B; HSPA1A |
| TNF signalling pathway | 7/110 | 1.65E-04 | MAPK10; AKT2; CASP3; MMP3; MAPK1; MAPK14; MMP9 |
TABLE 2 (Continued)

| Enriched biological pathways and processes | Overlap | Adjusted P-value | Genes |
|-------------------------------------------|---------|------------------|-------|
| Natural killer cell mediated cytotoxicity  | 7/131   | 4.24E-04         | ZAP70; LCK; CASP3; RAC2; MAPK1; RAF1; HRAS |
| Interferon-γ signalling pathway Homo sapiens P00035 | 3/20   | 7.82E-03         | MAPK10; MAPK1; MAPK14 |
| T-cell antigen receptor signalling pathway | 8/90    | 1.10E-05         | ITK; ZAP70; PDK1; LCK; MAPK1; RAF1; MAPK14; HRAS |
| TGF-β signalling pathway WP366            | 9/132   | 1.80E-05         | MMP12; MMP1; SRC; MAPK1; RAF1; MAPK14; met; PTK2; ROHA |
| IL-5 signalling pathway WP127            | 4/40    | 1.82E-03         | GSK3B; BTK; MAPK1; RAF1 |
| IL-2 signalling pathway WP49             | 4/42    | 2.10E-03         | LCK; MAPK1; RAF1; HRAS |
| IL-3 signalling pathway WP286            | 4/49    | 3.46E-03         | SRC; MAPK1; RAF1; HRAS |
| Neutrophil-mediated immunity (GO:0002446) | 26/487  | 1.21E-10         | CANT1; GSTP1; PYGL; CTSS; PLAU; MAPK1; CTSG; LTA4H; HSP90AA1; ACE; MME; NME2; RNASE3; MMP8; MAPK14; MMP9; ROHA; APRT; BST1; ADAM17; IMPDH1; IMPDH2; BPI; ALDOA; HSPA1B; HSPA1A |
| Neutrophil degranulation (GO:0043312)    | 24/479  | 1.94E-09         | HSP90AA1; CANT1; MME; GSTP1; NME2; RNASE3; PYGL; MMP8; MAPK14; MMP9; CTSS; ROHA; APRT; BST1; PLAU; IMPDH1; IMPDH2; MAPK1; CTSG; BPI; LTA4H; ALDOA; HSPA1B; HSPA1A |
| Neutrophil activation involved in immune response (GO:0002283) | 24/483  | 1.93E-09         | HSP90AA1; CANT1; MME; GSTP1; NME2; RNASE3; PYGL; MMP8; MAPK14; MMP9; CTSS; ROHA; APRT; BST1; PLAU; IMPDH1; IMPDH2; MAPK1; CTSG; BPI; LTA4H; ALDOA; HSPA1B; HSPA1A |
| Regulation of inflammatory response (GO:0050727) | 10/166  | 1.70E-04         | ACE2; BST1; PDE2A; PLA2G2A; NR1H4; NR1H3; PPARG; TEK; PPARA; MAPK14 |
| Myeloid leucocyte differentiation (GO:0002573) | 5/50    | 3.14E-03         | GLO1; kit; PPARG; MAPK14; MMP9 |
| Myeloid leucocyte mediated immunity (GO:0002444) | 9/20    | .04               | ADAM17; ace |
| Cellular response to cytokine stimulus (GO:0071345) | 13/456  | 5.15E-03         | GSK3B; HSP90AA1; MME; DAPK1; MAOA; MMP1; PDE2A; MMP3; MMP9; ROHA; CASP3; KIT; PI41A44D61A45A44:D67 |

Pharmmapper identified protein targets of pomalidomide and enriched biological processes and pathways

| Enriched biological pathways and processes | Overlap | Adjusted P-value | Genes |
|-------------------------------------------|---------|------------------|-------|
| T-cell receptor signalling pathway         | 15/101  | 9.64E-12         | ITK; GSK3B; MAP 2 K1; PDK1; MAPK14; IL2; ROHA; ZAP70; LCK; AKT2; AKT1; MAPK1; PRKQ; RAF1; HRAS |
| MAPK signalling pathway                    | 22/295  | 3.40E-11         | MAP 2 K1; IGF1; MAPK14; EGFR; TGFBR1; IGF1R; MAPK10; MAPK8; AKT2; CASP3; KIT; MAPKAPK2; KDR; RAC2; AKT1; MAPK1; TEK; RAF1; HRAS; MET; HSPA1B; HSPA1A |
| Neutrophil-mediated immunity (GO:0002446)  | 29/487  | 6.52E-11         | CDA; GPI; CANT1; ROCK1; GSTP1; ITGAL; CTSS; PLAU; MAPK1; CTSG; LTA4H; HSP90AA1; ACE; MME; NME2; RNASE3; MMP8; MAPK14; MMP9; ROHA; APRT; BST1; ADAM17; FABP5; IMPDH1; IMPDH2; BPI; ALDOA; HSPA1B; HSPA1A |
| T-cell antigen receptor signalling pathway | 12/90   | 4.23E-09         | ITK; ZAP70; MAP 2 K1; MAPK8; PDK1; LCK; AKT1; MAPK1; PRKQ; RAF1; MAPK14; HRAS |
| Osteoclast differentiation                 | 13/127  | 1.26E-08         | MAP 2 K1; SYK; MAPK14; TGFBR1; MAPK10; MAPK8; LCK; AKT2; CTSG; BTK; AKT1; MAPK1; PPARG |
| B-cell activation Homo sapiens P00010      | 21/94   | 1.49E-08         | MAPK10; MAP 2 K1; MAPK8; SYK; RAC2; BTK; MAPK1; RAF1; MAPK14; HRAS |
| Chemokine signalling pathway               | 15/190  | 2.41E-08         | ITK; GSK3B; MAP 2 K1; ROCK1; SRC; PTK2; ROHA; HCK; AKT2; RAC2; AKT1; MAPK1; RAF1; HRAS; JAK3 |
| IL-3 signalling pathway WP286              | 9/49    | 3.05E-08         | HCK; MAP 2 K1; MAPK8; SYK; SRC; AKT1; MAPK1; RAF1; HRAS |
| B-cell receptor signalling pathway         | 10/71   | 3.74E-08         | GSK3B; MAP 2 K1; SYK; AKT2; RAC2; BTK; AKT1; MAPK1; RAF1; HRAS |

(Continues)
elevated NF-κB signalling and rampage activation of immune response. Unlike other RNA viruses, SARS-CoV-2 suppresses TNF receptor-associated factors 3 activation, inhibiting NF-κB and IRFs, leading to suppression of early proinflammatory and antiviral responses. Whereas later stages of the infection show an enhanced expression of IRF targets in the lungs with an activation of IL-1, IL-6 and TNF-α expression and inhibition of type I interferon signalling. Activation of IRF and IFN-sensitive response element transcriptional targets in SARS-CoV-2 affected lungs is in agreement with previous studies reporting the SARS biology. Thalidomide inhibited LCK activity affecting STAT1 phosphorylation, cytokine mediated signalling, NF-κB signalling, osteoclast differentiation and MAPK signalling through modulation of various upstream activators and downstream effectors. Lenalidomide, in addition, suppressed leucocyte differentiation, TLR signalling along with IRF activation in A549 and lymphoma cells. The effects of thalidomide and lenalidomide observed in our study are consistent with the previous studies where thalidomide and lenalidomide has been shown to inhibit IRF and STAT1 phosphorylation resulting in the downregulation of interferon expression and TLR signalling.

The expression profile of SARS-CoV-2 infected lungs, PBMC as well as A549 cells show resemblance with profiles of lymphoma, multiple myeloma and SLE (Figure 2A); however, we have focused on SLE as there was a striking similarity of the SLE expression profile and enriched pathways with that of lungs affected by COVID-19 (Figure 2B). Interestingly, our findings showing the similarity of COVID-19 infected lung with SLE strongly support a recent study that identified the resemblance between severe cases of COVID-19 and SLE. We chose PBMC from SLE patients as it also captures the immune activity relatively better, and for better comparison with PBMC from COVID-19 patients and thalidomide-treated PBMC. Therefore, drugs that are effective in treating SLE, lymphoma and multiple myeloma might be effective against SARS-CoV-2 infection. Thalidomide and its derivatives show impressive efficacy in treating

**TABLE 2 (Continued)**

| Enriched biological pathways and processes | Overlap | Adjusted P-value | Genes |
|------------------------------------------|---------|------------------|-------|
| IL-17 signalling pathway                 | 11/93   | 4.19E-08         | MAPK10; GSK3B; HSP90AA1; MAPK8; MMP13; MMP1; CASP3; MMP3; MAPK1; MAPK14; MMP9 |
| Influenza A                              | 14/171  | 4.60E-08         | FDP5; GSK3B; MAP 2 K1; MAPK14; MAPK10; MAPK8; DDX39B; AKT2; CASP1; AKT1; MAPK1; RAF1; HSPA1B; HSPA1A |
| Viral carcinogenesis                      | 15/201  | 4.62E-08         | SYK; SRC; HDAC8; ROHA; CCNA2; KAT2B; CDK6; CASP3; CHEK1; MAPKAPK2; CDK2; MDM2; MAPK1; HRAS; JAK3 |
| Regulation of inflammatory response (GO:0050727) | 15/166  | 1.01E-07         | PDE2A; PLA2G2A; NR1H4; XIAP; NR1H3; MAPK14; IL2; ACE2; BST1; HCK; CASP1; PPARG; TEK; PPARA; PPARD |
| IL-5 signalling pathway WP127             | 8/40    | 1.06E-07         | GSK3B; MAP 2 K1; SYK; BTK; AKT1; MAPK1; RAF1; IL2 |
| TNF signalling pathway                    | 11/110  | 1.99E-07         | MAPK10; MAP 2 K1; CASP7; MAPK8; AKT2; CASP3; MMP3; AKT1; MAPK1; MAPK14; MMP9 |
| Interleukin signalling pathway Homo sapiens P00036 | 9/86    | 3.96E-06         | GSK3B; PDKP1; AKT2; MAPKAPK2; AKT1; MAPK1; RAF1; JAK3; IL2 |
| ACE inhibitor pathway WP554               | 5/17    | 5.33E-06         | ACE2; ACE; CTSG; REN; NR3C2 |
| Natural killer cell mediated cytotoxicity | 10/131  | 7.39E-06         | ZAP70; MAP 2 K1; SYK; LCK; CASP3; RAC2; MAPK1; RAF1; ITGAL; HRAS |
| FcγR-mediated phagocytosis                | 8/91    | 2.57E-05         | HCK; MAP 2 K1; SYK; AKT2; RAC2; AKT1; MAPK1; RAF1 |
| Toll-like receptor signalling pathway     | 8/104   | 6.29E-05         | MAPK10; MAP 2 K1; MAPK8; AKT2; CTSDK; AKT1; MAPK1; MAPK14 |
| Interferon-γ signalling pathway Homo sapiens P00035 | 4/20    | .001             | MAPK10; MAPK8; MAPK1; MAPK14 |
| Inflammation mediated by chemokine and cytokine Signalling pathway Homo sapiens P00031 | 9/188   | .001             | ROCK1; PDKP1; AKT2; AKT1; MAPK1; RAF1; ITGAL; IL2; ROHA |
| JAK–STAT signalling pathway               | 8/162   | 0.001            | AKT2; PIM1; AKT1; RAF1; HRAS; JAK3; IL2; EGFR |
| Toll-like receptor signalling pathway (GO:0002224) | 7/86    | 0.001            | CTSL; CTSDK; FGG; MAPKAPK2; BTK; NR1H4; CTSS |

*Overlap = the number of genes enriched in the category vs the total no of proteins contributing to the particular pathway/biological process. **Adjusted P-value denotes the P-value obtained after multiple testing.
multiple myeloma and certain forms of lymphoma. Notably, hydroxychloroquine, an Food and Drug Administration-approved SLE drug is currently being used in the management of critically ill SARS-CoV-2 patients. CC-220, another thalidomide analogue shows very promising results in phase I/II clinical trials against SLE. CC-220 through suppression of Ikaros and Aiolos expression, transcription factors that are essential for differentiation of leucocyte and NK cells, thus modulates the innate immune system. As innate immune system pathways are deregulated in SARS-CoV-2 infected lung and PBMC, further studies are warranted to investigate the efficacy and safety of CC-220 in treating COVID-19.

Any treatment strategy with thalidomide and its analogues including repurposing thalidomide for COVID-19, should consider thalidomide-induced adverse effects including neuropathy and venous thromboembolism. There have been many reports on COVID-19 patients develop blood clots, a dangerous issue that might be aggravated with the use of thalidomide and lenalidomide. In addition, lenalidomide might cause cytokine release syndrome in chronic lymphocytic leukaemia patients. Therefore, a very careful dosage regimen has to be followed with all these drugs as serious adverse effects have been observed during dose escalation.

5 | CONCLUSION

Our study sheds light on the possible mechanisms through which thalidomide and lenalidomide might be effective in the management of SARS-CoV-2 pathology. Thalidomide and derivatives effectively modulating various aberrantly regulated pathways infections with abundant pharmacological information available make them promising candidates for the treatment of novel coronavirus infections.

ACKNOWLEDGEMENTS

This project was partially supported by a grant from University Grant Commission-Faculty Recharge Programme (UGC-FRP), Government of India to S.C. The authors gratefully acknowledge Dr. Vijay Ramaswamy, Staff Neuro-oncologist and Scientist-Track Investigator, The Hospital for Sick Children, Toronto for critically reviewing the manuscript and providing valuable suggestions.

CONTRIBUTORS

L.S., S.G., H.S. and S.C. contributed to study design, experiments and data collection while L.S., S.G. and S.C. helped in manuscript preparation.

COMPETING INTERESTS

The authors have none to declare.

DATA AVAILABILITY STATEMENT

The data generated in this study have been deposited to Gene Expression Omnibus. The datasets that support this study are available in GEO at https://www.ncbi.nlm.nih.gov/geo/. BIG Data Center at https://bigd.big.ac.cn/ and ILINCS at http://www.ilincs.org/linces/. The appropriate references have been mentioned in the Methods section.

ORCID

Lakshmikirupa Sundaresan https://orcid.org/0000-0002-9534-7810
Suvendu Giri https://orcid.org/0000-0002-7595-1359
Suvro Chatterjee https://orcid.org/0000-0003-4413-9760

REFERENCES

1. Sungnak W, Huang N, Bécavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681-687. https://doi.org/10.1038/s41591-020-0868-6
2. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-422. https://doi.org/10.1016/S2213-2600(20)30076-X
3. Chen L, Liu H, Liu W, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie he he Hu Xi Za Zhi. 2020;43(0):E005.
4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395 (10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
5. Tay MZ, Poh CM, Rénia L, Mac Ary PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):1-12. https://doi.org/10.1038/s41577-020-0311-8
6. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120-128. https://doi.org/10.1056/NEJMoa2015432
7. Stephens TD, Bunde CJW, Fillmore BJ. Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol. 2000;59(12):1489-1499. https://doi.org/10.1016/S0006-2952(99)00388-3
8. Rehman W, Arfons LM, Lazarus HM. The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development. Ther Adv Hematol. 2011;2(5):291-308. https://doi.org/10.1177/2040621711413165
9. Rismanbaf A. Potential Treatments for COVID-19; a Narrative Literature Review. Arch Acad Emerg Med. 2020;8(1):e29. http://www.ncbi.nlm.nih.gov/pubmed/32232214
10. Chen C, Qi F, Shi K, et al. Thalidomide Combined with Low-Dose Glucocorticoid in the Treatment of COVID-19 Pneumonia. Preprints; 2020. www.preprints.org. Accessed May 20, 2020.
11. Khalil A, Kamar A, Nem er G. Thalidomide-Revisited: Are COVID-19 Patients Going to Be the Latest Victims of Yet Another Theoretical Drug-Repurposing? Front Immunol. 2020;11:291. https://doi.org/10.3389/fimmu.2020.00214
12. Wen H, Ma H, Cai Q, et al. Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma. Nat Med. 2018;24(2):154-164. https://doi.org/10.1038/nm.4456
13. Somogyi V, Chaudhuri N, Torrisi SE, Kahn N, Müller V, Kreuter M. The therapy of idiopathic pulmonary fibrosis: what is next? Eur Respir Rev. 2019;28(153):190021. https://doi.org/10.1183/16000617.0021-2019
14. Zhu H, Shi X, Ju D, Huang H, Wei W, Dong X. Anti-Inflammatory Effect of Thalidomide on H1N1 Influenza Virus-Induced Pulmonary Injury in Mice. Inflammation. 2014;37(6):2091-2098. https://doi.org/10.1007/s10753-014-9943-9
15. Li D, Zhang X-W, Jiang X-Q, et al. Protective effects of thalidomide on pulmonary injuries in a rat model of paraquat intoxication.
54. Majumder S, Rajaram M, Muley A, et al. Thalidomide attenuates nitric oxide signaling. J Cancer Res Ther. 2018;14(Supplement):S237-S242. https://doi.org/10.4103/0973-1482.183181

55. Shannon E, Aseffa A, Pankey G, Sandoval F, Lutz B. Thalidomide's effects on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177(6):1675-1680.

56. Pellagatti A, Jadersten M, Forsblom A-M, et al. Lenalidomide inhibits the ability to augment the synthesis of IL-2 in vitro in HIV-infected patients. Clin Immunol. 1996;81(3):219-223. https://doi.org/10.1006/clin.1996.0018.

57. Yang Z, Wen R, Zhang Y, et al. Thalidomide induces response in gastric cancer cell line SGC7901/vincristine Notch signaling. J Cancer Res Ther. 2018;14(Supplement):S225-S229. https://doi.org/10.4103/0973-1482.183049.

58. Huang H, Yan G, Su H, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177(6):1675-1680.

59. Phung TTB, Sugamata R, Uno K, et al. Key role of regulated upon activation normal T-cell expressed and secreted, nonstructural protein1-myeloperoxidase in cytokine storm induced by influenza virus PR-8 (A/H1N1) infection in A549 bronchial epithelial cells. Microb Immunol. 2011;55(12):874-884. https://doi.org/10.1111/j.1348-0421.2011.00396.x

60. Lin Y-C, Shun C-T, Wu M-S, Chen C-C. A Novel Anticancer Effect of Thalidomide: Inhibition of Intercellular Adhesion Molecule-1-Mediated Cell Invasion and Metastasis through Suppression of Nuclear Factor-B. Clin Cancer Res. 2006;12(23):7165-7173. https://doi.org/10.1158/1078-0432.CCR-06-1393.
78. Aue G, Njuguna N, Tian X, et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. *Haematologica*. 2009;94(9):1266-1273. https://doi.org/10.3324/haematol.2009.005835

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Sundaresan L, Giri S, Singh H, Chatterjee S. Repurposing of thalidomide and its derivatives for the treatment of SARS-CoV-2 infections: Hints on molecular action. *Brit Jnl Clinical Pharma*. 2021;1–16. https://doi.org/10.1111/bcp.14792